Rejected from International Journal of Molecular Sciences? The 6 Best Journals to Submit Next
Rejected from IJMS? Explore 6 strong alternative journals ranked by scope fit, impact factor, and acceptance rate to find the best home for your molecular sciences paper.
Senior Researcher, Oncology & Cell Biology
Author context
Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.
Next step
Choose the next useful decision step first.
Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.
The International Journal of Molecular Sciences is one of the highest-volume open-access journals in the molecular sciences, publishing over 10,000 articles per year across molecular biology, biochemistry, physical chemistry, and pharmacology. Published by MDPI, IJMS has an impact factor around 5 and an acceptance rate of approximately 40-50%. That makes it one of the more accessible journals in the molecular sciences. So when IJMS rejects your paper, it's worth taking the feedback seriously, because the issues identified are likely to follow you to other journals.
Quick answer
After an IJMS rejection, your options depend on the rejection reason. If the methodology was the problem, fix it before going anywhere. For molecular biology papers, PLOS ONE (IF ~3) and Molecules (IF ~4, also MDPI) are accessible alternatives. For biochemistry, the International Journal of Biological Macromolecules (IF ~7) is a strong option. For papers that are stronger than IJMS's threshold, consider moving up to Molecular Cell (IF ~17) or Nucleic Acids Research (IF ~15) if the work justifies it.
Why International Journal of Molecular Sciences rejected your paper
IJMS has a broad scope and relatively high acceptance rate, so rejections typically indicate specific identifiable problems rather than vague editorial judgment calls.
Methodological problems
The most common rejection reason at IJMS is weak methodology. Insufficient sample sizes, missing controls, inappropriate statistical tests, and unreproducible protocols are flagged frequently. Because IJMS receives papers from a wide range of research environments globally, the editorial team has developed efficient screening for these issues. If the reviewers cited methodological concerns, those concerns are almost certainly valid and need to be addressed.
Poor English language quality
IJMS has a diverse international author base, and language quality is a genuine barrier to publication. Papers with frequent grammatical errors, unclear sentence structure, or ambiguous scientific descriptions are rejected or returned for language editing. Unlike some journals that accept papers contingent on language revision, IJMS sometimes rejects outright if the language issues are severe enough that reviewers can't evaluate the science.
Scope misalignment
Despite its broad title, IJMS focuses on molecular-level science. Papers that are purely clinical, purely computational without molecular validation, or purely engineering without molecular insight may fall outside the scope. The "molecular sciences" in the title means the journal wants molecular mechanisms, molecular interactions, or molecular characterization as the core of the paper.
Insufficient novelty for special issues
IJMS publishes many special issues with guest editors. If you submitted to a special issue, the guest editors have specific expectations for the collection they're building. Rejection from a special issue doesn't mean the paper is weak overall. It may mean it didn't fit the guest editor's vision for that particular issue.
The 6 best alternative journals
Journal | Impact Factor | Acceptance Rate | Best For | APC | Typical Review Time |
|---|---|---|---|---|---|
PLOS ONE | ~3 | ~50% | Any molecular science, broad scope | $1,931 | 4-8 weeks |
Molecules | ~4 | ~45% | Chemical biology, natural products | $2,790 | 4-6 weeks |
International Journal of Biological Macromolecules | ~7 | ~25% | Biochemistry, protein science | $3,500 (OA option) | 6-10 weeks |
Cells | ~5 | ~40% | Cell biology, molecular cell science | $2,790 | 4-6 weeks |
Biomolecules | ~5 | ~45% | Protein structure, enzymology | $2,790 | 4-6 weeks |
Frontiers in Molecular Biosciences | ~4 | ~40% | Molecular biology, bioinformatics | $2,950 | 6-12 weeks |
1. PLOS ONE
PLOS ONE is the most broadly accessible alternative for any molecular sciences paper. The journal evaluates scientific validity and methodological soundness rather than novelty or perceived impact, which means a well-designed study that IJMS rejected for "insufficient novelty" can find a home here. PLOS ONE's acceptance rate (~50%) is comparable to IJMS's, but the review criteria are different. The APC ($1,931) is lower than most alternatives, and the journal's open-access model ensures broad visibility.
Best for: Methodologically sound papers with incremental results, confirmatory studies, any molecular science discipline.
2. Molecules
Molecules is another MDPI journal, focused on chemistry and chemical biology, including natural products, synthetic chemistry, and molecular interactions. If your IJMS paper had a chemistry angle, Molecules may be a more targeted scope match. The editorial process is similar to IJMS (same publisher, similar timeline), and the impact factor (~4) is comparable. If IJMS rejected your paper for scope reasons, Molecules may be the right MDPI journal for your specific topic.
Best for: Natural product chemistry, drug design, chemical biology, molecular interactions and recognition.
3. International Journal of Biological Macromolecules
IJBM publishes research on biological macromolecules: proteins, nucleic acids, polysaccharides, and lipids. The impact factor (~7) is higher than IJMS, so this is a step up if your paper is strong enough. The journal is published by Elsevier and has a well-established reputation in biochemistry and biopolymer science. If your IJMS paper focused on protein characterization, enzyme kinetics, or polysaccharide properties, IJBM's specialized scope gives you access to reviewers who understand the work deeply.
Best for: Protein biochemistry, polysaccharide characterization, enzyme studies, biopolymer applications.
4. Cells
Cells (MDPI) focuses on cell biology at the molecular level, covering cell signaling, cell death, organelle biology, and cellular disease mechanisms. If your IJMS paper was cell biology research with molecular characterization, Cells may be a better scope fit. The impact factor (~5) is comparable, and the editorial process is familiar if you've already submitted to IJMS. Cells is growing quickly and has established a solid reputation in the cell biology community.
Best for: Cell signaling, apoptosis and autophagy, organelle function, cellular disease mechanisms.
5. Biomolecules
Biomolecules (MDPI) covers the structure, function, and interactions of biological molecules, with emphasis on proteins, enzymes, and nucleic acids. The scope is narrower than IJMS, which can be an advantage. Your paper competes against a smaller pool of submissions, and the reviewers are specifically interested in biomolecular science. For structural biology, enzymology, and protein-protein interaction studies that IJMS rejected, Biomolecules is a natural alternative.
Best for: Protein structure and function, enzyme mechanisms, nucleic acid biochemistry, molecular interactions.
6. Frontiers in Molecular Biosciences
Frontiers in Molecular Biosciences covers molecular biology, structural biology, and bioinformatics. The Frontiers editorial model uses a collaborative review process where authors and reviewers interact directly, which can be more constructive than traditional peer review. If IJMS reviewers gave you feedback that seemed misaligned with your paper's goals, Frontiers' interactive process may lead to a more productive review. The impact factor (~4) is comparable.
Best for: Molecular biology, structural biology, bioinformatics, molecular mechanisms of disease.
The cascade strategy
Rejected for methodology? Fix every methodological issue before submitting anywhere. Add the missing controls, increase sample sizes if possible, and get a statistician to review your analysis. Methodological problems don't disappear at a new journal.
Rejected for language quality? Invest in professional English editing. This isn't optional. If IJMS flagged language issues, every other journal will see the same problems. Professional editing services typically cost $200-500 and save months of rejection-revision cycles.
Rejected from a special issue? Submit as a regular article to IJMS (if the rejection letter allows it), or send it to one of the alternative journals listed above. Special issue rejections often reflect the guest editor's preferences rather than the paper's quality.
Rejected for "insufficient novelty"? PLOS ONE evaluates validity rather than novelty. Alternatively, consider whether the paper's contribution is actually more specialized than IJMS's broad scope. A focused journal like Biomolecules or Cells may see more novelty in work that IJMS considered routine.
Paper is stronger than you initially thought? If IJMS rejected for scope rather than quality, and you now realize the work is more significant than an IJMS-level paper, consider submitting to International Journal of Biological Macromolecules (IF ~7) or even a higher-tier journal in your specific field.
What to change before resubmitting
Get your methods section right. Describe every protocol in enough detail that another lab could reproduce your work. Include catalog numbers for reagents, specific instrument models, and exact software versions for analysis. IJMS and its alternatives are all tightening their standards for reproducibility.
Invest in language editing. Professional editing is the single highest-return investment for papers rejected on language grounds. Don't rely on co-authors who are also non-native English speakers to catch language issues. An external editor brings fresh eyes and native fluency.
Check your figures. Are they clear at the size they'll appear in the published article? Are the labels readable? Are the error bars defined? Figure quality is the first thing editors notice when scanning a submission, and poor figures create a negative first impression that's hard to overcome.
Verify your statistical analysis. If you're using t-tests, make sure the data meets the assumptions. If you're doing multiple comparisons, apply the appropriate correction. If your sample size is small, acknowledge the limitation and consider non-parametric alternatives. Statistical errors are the most common preventable rejection reason across all molecular science journals.
Before you resubmit
Every rejection is an opportunity to make the paper stronger, but only if you actually use the feedback. Before submitting to the next journal, run your manuscript through a free Manusights scan to identify remaining formatting, methodology, and scope alignment issues. Catching problems before reviewers do is always faster than going through another review cycle.
Sources
Reference library
Use the core publishing datasets alongside this guide
This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.
Dataset / reference guide
Peer Review Timelines by Journal
Reference-grade journal timeline data that authors, labs, and writing centers can cite when discussing realistic review timing.
Dataset / benchmark
Biomedical Journal Acceptance Rates
A field-organized acceptance-rate guide that works as a neutral benchmark when authors are deciding how selective to target.
Reference table
Journal Submission Specs
A high-utility submission table covering word limits, figure caps, reference limits, and formatting expectations.
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.